FDAnews Drug Daily Bulletin
Pharmaceuticals / Research and Development

The Medicines Company Discontinues Development of MDCO-216

Nov. 14, 2016

The Medicines Company has terminated the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.

Data from the pilot trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development.

View today's stories